eGFR Sex- and Cycle-Related Differences: What Every Patient on GLP-1, Metformin, or HRT Needs to Know

Why eGFR Is Not a Sex-Neutral Number

Estimated glomerular filtration rate is calculated from serum creatinine, age, and sex, yet the serum creatinine level itself is a product of muscle mass, dietary protein intake, and tubular secretion, all of which differ substantially between sexes. The CKD-EPI 2021 equation removed race as a variable but retained sex as a required input precisely because ignoring it produces systematic error. Inker et al., NEJM 2021 showed that across 10 validation cohorts (N = 1,248,040 eGFR measurements), the race-free CKD-EPI 2021 equation achieved a bias of less than 5% in both sexes when sex was correctly coded. [1]

The Creatinine-Muscle-Mass Problem

Men carry roughly 35-40% of body weight as skeletal muscle versus 25-30% in women, generating proportionally more creatinine per kilogram. A serum creatinine of 0.9 mg/dL in a 55 kg woman and a 90 kg man represent very different filtration states. The CKD-EPI 2021 formula applies a sex-specific coefficient (0.9 for women, 1.0 for men in the kappa denominator) to partially correct this, but it still underestimates true GFR in women with sarcopenia and overestimates it in heavily muscled men. Levey et al., AJKD 2020 documented a mean bias of +4.9 mL/min/1.73 m² in women with cancer-related muscle wasting using the creatinine-only equation. [2]

Cystatin C as the Sex-Neutral Alternative

Cystatin C, a 13 kDa protease inhibitor filtered freely at the glomerulus, is produced at a relatively constant rate by all nucleated cells regardless of muscle mass. The combined CKD-EPI creatinine-cystatin C equation (eGFRcr-cys) reduces the sex-based bias to under 2 mL/min/1.73 m² in most validation studies. Stevens et al., AJKD 2008 found that eGFRcys reclassified 19.4% of women previously placed in CKD stage G3a by creatinine-only equations into stage G2, a difference that directly affects prescribing decisions. [3]

How the Menstrual Cycle Shifts eGFR

The ovarian cycle produces two major hormonal swings, an estrogen peak at ovulation and a progesterone-dominant luteal phase, both of which alter renal hemodynamics. Estrogen acts on endothelial nitric oxide synthase to increase renal plasma flow, while progesterone is natriuretic and mildly dilates the renal collecting system. Together they produce a reproducible intra-cycle eGFR rhythm that clinicians routinely miss.

Follicular Phase Baseline

During days 1-12 of a standard 28-day cycle, estradiol rises from roughly 30 pg/mL to 200-400 pg/mL at the preovulatory surge. Davison et al., Am J Physiol 2004 measured 24-hour creatinine clearance across four cycle phases in 12 healthy women and found follicular-phase clearance of 108 ± 12 mL/min, serving as the functional baseline. [4]

Luteal Phase Rise

Progesterone peaks at 10-20 ng/mL between days 19-23. In the same Davison cohort, mid-luteal creatinine clearance rose to 127 ± 14 mL/min, a 17.6% increase over the follicular baseline. [4] The mechanism involves progesterone-driven vasodilation of the afferent arteriole and a small but measurable decrease in serum creatinine, which feeds directly into eGFR calculators and can make a woman appear to have better kidney function than she does at other times of the month.

Clinical Consequence: Timing of Lab Draws

A woman being evaluated for CKD staging should ideally have labs drawn in the follicular phase (days 2-5 from menstrual onset) to capture her stable baseline rather than a cycle-inflated luteal reading. Collecting labs at the luteal peak may mask early CKD stage G3a (eGFR 45-59) by pushing the reported value above 60 mL/min/1.73 m². Maric-Bilkan et al., Clin J Am Soc Nephrol 2017 recommended standardizing the timing of GFR assessments to the early follicular phase in reproductive-age women whenever CKD staging has treatment implications. [5]

Pregnancy: The Largest Physiologic GFR Surge

Pregnancy produces the most dramatic GFR shift encountered outside of pharmacologic intervention. Renal plasma flow increases 40-80% by the second trimester driven by progesterone, relaxin, and reduced systemic vascular resistance. EGFR peaks between weeks 9 and 16 at 140-170 mL/min in women with normal pre-pregnancy function.

What This Means for Drug Thresholds

Metformin is renally cleared, and the FDA label (accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf) contraindicates use when eGFR falls below 30 mL/min/1.73 m² and recommends reassessment at eGFR 30-45. [6] During pregnancy this threshold is rarely reached, but the postpartum drop back to pre-pregnancy GFR within 6-8 weeks can catch clinicians off guard if metformin was started or up-dosed in the second trimester. Piccoli et al., BMJ 2018 documented a mean postpartum eGFR decline of 38 mL/min/1.73 m² in women who had pre-existing CKD, a magnitude sufficient to cross multiple dosing thresholds simultaneously. [7]

Pre-eclampsia and Sudden eGFR Drops

Pre-eclampsia impairs glomerular filtration acutely. A serum creatinine of 1.0 mg/dL, which would generate an eGFR of roughly 70 mL/min/1.73 m² in a non-pregnant 30-year-old woman, represents a doubling of baseline in a pregnant woman whose creatinine should be below 0.5 mg/dL in the second trimester. Cornelis et al., NDT 2010 reviewed 652 pregnancies in women with CKD and found that pre-eclampsia occurred in 40% of those with stage G3 disease. [8]

Menopause, Estrogen Loss, and the Long-Term GFR Trajectory

Menopause marks the end of the cyclic GFR rhythm and introduces a sustained estrogen-deficient state that accelerates age-related GFR decline. The SWAN (Study of Women's Health Across the Nation) cohort study followed 3,302 women through the menopausal transition. Hsu et al., JASN 2010 found that women who entered menopause before age 45 (premature ovarian insufficiency) had a 32% higher odds of CKD (eGFR <60 mL/min/1.73 m²) by age 60 compared with women with natural menopause at age 50-52. [9]

Estrogen's Renoprotective Mechanisms

Estrogen suppresses the intrarenal renin-angiotensin system, reduces TGF-beta-driven fibrosis, and maintains endothelial nitric oxide bioavailability in the afferent arteriole. Loss of these effects after menopause corresponds to the well-documented acceleration in GFR decline from roughly 0.75 mL/min/1.73 m²/year in premenopausal women to 1.0-1.4 mL/min/1.73 m²/year in the decade after menopause. Carrero et al., Nat Rev Nephrol 2018 summarized this trajectory across seven longitudinal cohorts. [10]

Does Hormone Therapy Preserve eGFR?

The data on estrogen-containing HRT and kidney function are mixed but cautiously favorable. The Women's Health Initiative (WHI) randomized 16,608 postmenopausal women to conjugated equine estrogen plus medroxyprogesterone acetate versus placebo. A secondary analysis by Haring et al., CJASN 2017 found that women on combined HRT had a 16% lower incidence of eGFR decline below 60 mL/min/1.73 m² over 5.6 years of follow-up compared with placebo (HR 0.84, 95% CI 0.73-0.97). [11] The effect was driven primarily by the estrogen-alone arm in women who had undergone hysterectomy. Transdermal estradiol, which avoids first-pass hepatic activation of the renin-angiotensin system, may confer a cleaner renoprotective effect than oral formulations, though direct head-to-head renal outcome data remain limited.

Testosterone, TRT, and eGFR in Men and Women

Testosterone is not merely a male hormone; it affects GFR biology in both sexes through androgen receptors on renal tubular and mesangial cells. Higher testosterone promotes creatinine production independent of GFR, which means men on testosterone replacement therapy (TRT) may show a fall in calculated eGFR that reflects increased creatinine generation rather than genuine nephron loss.

TRT-Induced Creatinine Rise

Traish et al., J Sex Med 2011 documented a mean serum creatinine increase of 0.08 mg/dL within 12 weeks of initiating TRT in 130 hypogonadal men. [12] In a man with baseline creatinine of 1.0 mg/dL and eGFR of 85 mL/min/1.73 m², this shift alone would lower the calculated eGFR to approximately 77 mL/min/1.73 m² without any change in actual nephron filtration. Cystatin C-based eGFR does not carry this artifact and is the preferred monitoring tool in men newly started on TRT.

Women on Testosterone Therapy

Women prescribed low-dose testosterone (typically 0.5-2 mg/day topical or 50-100 mg pellet) for libido or energy also see small creatinine increases. The magnitude is roughly half that seen in men given full TRT doses, but in a woman already near a dosing threshold (eGFR 32 mL/min/1.73 m² on metformin, for example), even a 0.04 mg/dL creatinine artifact could trigger an unnecessary drug hold. Ordering a cystatin C at baseline and again 8-12 weeks after testosterone initiation clarifies whether any eGFR change is real.

What Is the Optimal eGFR? Staging vs. Longevity Targets

The KDIGO 2022 CKD guidelines (kdigo.org/guidelines/ckd-evaluation-management/) define eGFR categories as G1 (≥90), G2 (60-89), G3a (45-59), G3b (30-44), G4 (15-29), and G5 (<15), all in mL/min/1.73 m². [13] "Normal" by this schema is anything above 60. Longevity medicine sets a higher bar.

Population Data on Mortality Risk

A meta-analysis of 46 cohorts (N = 2,051,244 participants) by Matsushita et al., Lancet 2010 found that all-cause mortality risk began rising measurably at eGFR below 75 mL/min/1.73 m², well above the clinical CKD threshold of 60. [14] The hazard ratio for cardiovascular death at eGFR 60-74 versus eGFR 90-104 was 1.20 (95% CI 1.15-1.26), a 20% excess risk that is often dismissed as "normal aging." The HealthRX longevity target of 90-120 mL/min/1.73 m² for adults under 60 derives from this curve: eGFR values in that range sit on the flat, low-risk portion of the mortality hazard function.

Age-Related Decline and When to Investigate

GFR declines at roughly 0.75-1.0 mL/min/1.73 m²/year after age 40 in healthy adults. A 45-year-old woman with eGFR 68 mL/min/1.73 m² is "normal" by KDIGO but sits 22 mL/min/1.73 m² below the longevity target and may reach G3a by age 60 without any modifiable intervention. Identifying that trajectory early, before albuminuria appears, is one reason the HealthRX panel includes cystatin C rather than creatinine alone.

Drug Dosing Thresholds Controlled by eGFR

GLP-1 Receptor Agonists

Semaglutide (Ozempic, Wegovy) is primarily metabolized by proteolytic cleavage, not renal filtration. The FDA prescribing information (accessdata.fda.gov/drugsatfda_docs/label/2021/213051s000lbl.pdf) states no dose adjustment is required for any degree of renal impairment, including end-stage kidney disease. [15] Liraglutide (Victoza, Saxenda) carries a similar label. Tirzepatide (Mounjaro, Zepbound) likewise requires no renal dose adjustment per its FDA label. Despite these labels, post-marketing pharmacovigilance has documented acute kidney injury in patients on GLP-1 agonists who develop severe nausea-related dehydration. Checking eGFR before and 4-8 weeks after GLP-1 initiation remains standard HealthRX practice.

Metformin

The FDA label for metformin (accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf) contraindicates metformin at eGFR <30 mL/min/1.73 m² and recommends assessing risk-benefit at eGFR 30-45 mL/min/1.73 m² due to lactic acidosis risk. [6] Because cycle-phase variation can swing eGFR by up to 20%, a woman with true GFR near 50 mL/min/1.73 m² might read 58 at luteal peak and 46 during menses, technically triggering a caution label in the follicular phase. Drawing metformin eligibility labs on cycle day 2-5 removes this ambiguity.

SGLT2 Inhibitors

Empagliflozin (Jardiance) lost its glucose-lowering indication below eGFR 45 but retains its heart failure and CKD indications (for cardioprotection and nephroprotection) down to eGFR 20 per the 2023 FDA label update. Dapagliflozin (Farxiga) for CKD may be used down to eGFR 25. Heerspink et al., NEJM 2020 (DAPA-CKD, N = 4,304) showed dapagliflozin reduced the composite of sustained 50% eGFR decline, end-stage kidney disease, or renal or cardiovascular death by 39% versus placebo (HR 0.61, 95% CI 0.51-0.72, P<0.001). [16]

Which eGFR Equation to Use: A Practical Guide by Patient Type

| Patient Profile | Recommended Equation | Reason | |---|---|---| | Average adult, normal muscle mass | CKD-EPI 2021 (creatinine) | Best validated, no race variable | | Woman with low BMI or sarcopenia | CKD-EPI cystatin C or combined | Creatinine underestimates true GFR | | Man on TRT or high-protein diet | CKD-EPI cystatin C or combined | Creatinine overestimates muscle-derived GFR decline | | Pregnant woman | Measured 24-hr urine creatinine clearance | Pregnancy invalidates all CKD-EPI equations | | Child or adolescent | Bedside Schwartz equation | CKD-EPI not validated under age 18 | | Acute kidney injury workup | Serum cystatin C trend, not eGFR | eGFR assumes steady-state creatinine |

Practical Protocol: When to Recheck and What to Order

Checking eGFR once and filing the result misses the sex-hormone dynamic entirely. The HealthRX protocol for women of reproductive age includes a baseline draw on cycle days 2-5, a repeat at 12 weeks on any new hormonal therapy (HRT, testosterone, hormonal contraception), and an annual paired creatinine-plus-cystatin C panel to calculate eGFRcr-cys. For men starting TRT, eGFRcr-cys is drawn at baseline and at 12 weeks; creatinine-only eGFR is not used to make dose-hold decisions during the first 6 months of therapy.

The KDIGO 2022 guideline statement on cystatin C reads: "We recommend using cystatin C to confirm CKD in adults with eGFRcr 45-59 mL/min/1.73 m² who do not have markers of kidney damage, because this may avoid misclassification." [13] That recommendation applies with particular force to women in the mid-cycle luteal phase and to anyone on hormonal therapy.

The single most actionable step for any clinician reviewing a low eGFR in a premenopausal woman: check where in her cycle the blood was drawn. If the answer is unknown, repeat the creatinine and cystatin C on days 2-5 of the next cycle before staging or changing medications.